Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

Bunitrolol

From Wikipedia, the free encyclopedia
Bunitrolol
Names
IUPAC name
2-[3-(tert-Butylamino)-2-hydroxypropoxy]benzonitrile
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
KEGG
UNII
  • InChI=1S/C14H20N2O2/c1-14(2,3)16-9-12(17)10-18-13-7-5-4-6-11(13)8-15/h4-7,12,16-17H,9-10H2,1-3H3
    Key: VCVQSRCYSKKPBA-UHFFFAOYSA-N
  • InChI=1/C14H20N2O2/c1-14(2,3)16-9-12(17)10-18-13-7-5-4-6-11(13)8-15/h4-7,12,16-17H,9-10H2,1-3H3
    Key: VCVQSRCYSKKPBA-UHFFFAOYAU
  • CC(C)(C)NCC(COC1=CC=CC=C1C#N)O
Properties
C14H20N2O2
Molar mass 248.326 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Bunitrolol is a beta-adrenergic antagonist.[1]

Synthesis

[edit]

2-Hydroxybenzonitrile (1) is treated with epichlorohydrin and sodium hydroxide to give the epoxide (2). Addition of tert-butylamine completes the synthesis of bunitrolol.[2]

See also

[edit]

References

[edit]
  1. Haddad, S; Poulin, P; Funk, C (2010). "Extrapolating in vitro metabolic interactions to isolated perfused liver: Predictions of metabolic interactions between R-bufuralol, bunitrolol, and debrisoquine". Journal of Pharmaceutical Sciences. 99 (10): 4406–26. doi:10.1002/jps.22136. PMID 20310018.
  2. Herbert Koppe, Albrecht Engelhardt, Karl Zeile, U.S. patent 3,940,489 (1976 to Boehringer Ingelheim Gmbh).